
Sign up to save your podcasts
Or


In this episode of Forward Thinking, we’ll hear an interview with one of the leading technology strategists in the world: Kevin Scott. Kevin is the chief technology officer and vice president of artificial intelligence and research at Microsoft. He also has a new book out called Reprogramming the American Dream.
The interview is conducted by MGI’s own James Manyika, who is a co-chairman and director of the McKinsey Global Institute, and a senior partner at McKinsey & Company. He’s also a deep expert in his own right when it comes to artificial intelligence and machine learning. That’s why James sat down with Kevin to discuss how AI might be the key to democratizing technology to work better for all of us.
This conversation was recorded in May 2020.
To read a transcript of this episode, visit: https://mck.co/forwardthinking
Follow @McKinsey_MGI on Twitter and the McKinsey Global Institute on LinkedIn for more.
See www.mckinsey.com/privacy-policy for privacy information
Diane Coyle is known for her critique of how economic activity has been measured and valued. She’s written about how transactions are counted in dollars, but that accounting really leaves out important things like physical resources, intellectual resources, and valuable activity that isn't traded for money.
In this episode, we speak to hear to understand more about why this matters, how to rectify this measurement, and whether she’s optimistic about the future after COVID-19.
This conversation was recorded in February 2021.
To read a transcript of this episode, visit: mck.co/forwardthinking
Follow @McKinsey_MGI on Twitter and the McKinsey Global Institute on LinkedIn for more.
See www.mckinsey.com/privacy-policy for privacy information
You’ve heard about the Industrial Revolution and the digital revolution. But now, we’re heading into a Bio Revolution. And this is going to transform the economy and society in many ways—even beyond health and agriculture. And we need to understand both the potential for good and how to avoid the pitfalls.
In this episode, we start with a picture of the science that’s happening, then explore where might these advances lead. Our guests are two people doing truly amazing work literally on the very frontiers of where these advances are taking place. Jason Kelly is the founder of Ginkgo Bioworks, a biotech company that describes itself as “the organism company.” And Dr. Michelle McMurry-Heath is the president and CEO of the Biological Innovation Organization (BIO).
Interview date: November 2020
To read more about the Bio Revolution, visit: mck.co/biorev To read a transcript of this episode, visit: mck.co/forwardthinking
Follow @McKinsey_MGI on Twitter and the McKinsey Global Institute on LinkedIn for more.
See www.mckinsey.com/privacy-policy for privacy information
As part of Black History Month, MGI co-chair James Manyika had an open, candid conversation with Mellody Hobson and an audience of McKinsey colleagues in the San Francisco office. “You can almost pick any arena you want in American business, society, and community, and I think you’ll probably find Mellody involved, playing some important pioneering role there.” From her childhood on the South Side of Chicago, to Princeton, to leading Ariel Investments and now chairing the board of Starbucks, Mellody Hobson is an inspirational business leader and investor. She shares her journey, a peek into her how she sees her work, and gives advice on mentorship, sponsorship, and difficult feedback. On that note, she says: “Accept it, do not push back, do not fight. If this feedback is a gift, take it for what it is.”
This conversation was recorded on February 21, 2020.
To read a transcript of this episode, visit: mck.co/mellodyhobson
Follow @McKinsey_MGI on Twitter and the McKinsey Global Institute on LinkedIn for more.
See www.mckinsey.com/privacy-policy for privacy information
The Bio Revolution has the potential to transform our lives, and genome editing—the ability to change the DNA sequence in a targeted way using CRISPR-Cas9, is one of the key innovations that has sparked imaginations while also raising its fair share of controversy. What is the origin of this technique? How do we weigh the enormous benefits against the potential risks? And what is its role in solving the global coronavirus pandemic? As part of the McKinsey Global Institute’s research on the Bio Revolution, partner Michael Chui spoke with Jennifer Doudna, PhD, one of the scientists who discovered the genome-editing technique CRISPR-Cas9 and leading proponent of its responsible use. Jennifer is a professor of molecular and cell biology and chemistry at the University of California, Berkeley. The Doudna lab pursues a mechanistic understanding of fundamental biological processes involving RNA molecules.
To read a transcript of this episode, visit: mck.co/3dEJWhJ
To read more about the Bio Revolution, visit: mck.co/biorev
See www.mckinsey.com/privacy-policy for privacy information
We ask these questions (and more) to Sir Chris Pissarides, He’s a Nobel prize-winning economist, the professor of economics at London School of Economics, and professor of European studies at the University of Cyprus. Chris specializes in labor markets, macroeconomic policy, economic growth, and structural change.
This conversation was recorded in February 2021.
To read a transcript of this episode, visit: mck.co/forwardthinking
Follow @McKinsey_MGI on Twitter and the McKinsey Global Institute on LinkedIn for more.
See www.mckinsey.com/privacy-policy for privacy information
See www.mckinsey.com/privacy-policy for privacy information
See www.mckinsey.com/privacy-policy for privacy information
See www.mckinsey.com/privacy-policy for privacy information
See www.mckinsey.com/privacy-policy for privacy information
From the publisher's feed

175 Listeners

167 Listeners